You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Dual Targeting in OCD Neuromodulation: Lessons from the UCL OCD DBS Trial & Next-Generation Brain Stimulation for Obsessive-Compulsive Disorder
Part 1: Dual Targeting in OCD Neuromodulation: Lessons from the UCL OCD DBS Trial Presented by Himanshu Tyagi, MRCPsych, PhD
- Understand the evolution of OCD DBS Targeting;
- Understand the core functional circuits involved in OCD;
- Clinical lessons learnt from OCD DBS Dual Targeting;
- Impact on disability and the burden of normality after the successful treatment of OCD.
Part 2: Next-Generation Brain Stimulation for Obsessive-Compulsive Disorder Presented by Alik Widge, MD, PhD
- Describe the clinical evidence for invasive neurostimulation in psychiatry;
- Identify challenges unique to the design of clinical trials in brain stimulation;
- Describe the application of biomarker-based therapies to improve clinical neurostimulation outcomes.
Date of Release: July 9, 2021
Date of Expiration: July 8, 2023
Cost: Members: $25 | Non-members $50 | Student Members FREE
Himanshu Tyagi, MRCPsych, PhD
Dr Himanshu Tyagi, MRCPsych, PhD is a medical psychotherapist and clinical academic neuropsychiatrist in the field of obsessive-compulsive and related disorders. He coordinated the first UK trial investigating Deep Brain Stimulation (DBS) in severe and treatment refractory obsessive-compulsive disorder (OCD) between 2012-2016 at UCL Queen Square Institute of Neurology. He holds a CCT in Psychotherapy (CBT), a PhD in neuroscience from UCL and was the recipient of Higher Psychiatric Trainee of the Year award from the Royal College of Psychiatrists, UK in 2012 and British Neuropsychiatric Association’s Alwyn Lishman prize in 2017. He is also a co-founder and vice chair of the Royal College of Psychiatrists network for Obsessive-Compulsive and Related Disorders (OCARD). At present he runs a specialist national clinic for OCD comorbid with Tourette syndrome at the National Hospital for Neurology and Neurosurgery, Queen Square and leads one of two specialist inpatient OCD services in England which is based in North London. He is also a co-investigator on the upcoming Op-TICS trial, looking at deep brain stimulation in patients with severe Tourette Syndrome. He routinely tweets about the latest OCD research and clinical practice tips at @himanshutyagi
Alik Widge, MD, PhD
Alik Widge, MD, PhD is a brain stimulation psychiatrist and biomedical engineer. He is an Assistant Professor of Psychiatry at the University of Minnesota, where he directs the Translational NeuroEngineering Lab. Dr. Widge completed his MD at the University of Pittsburgh, his PhD in Robotics at Carnegie Mellon University, psychiatry residency at the University of Washington, and fellowships at Massachusetts General Hospital and the Massachusetts Institute of Technology. His research focuses on brain stimulation for severe and treatment-resistant mental illness, with particular emphasis on deep brain stimulation and related implantable technologies. Dr. Widge's recent work has demonstrated new algorithms for closed-loop brain stimulation and stimulation methods for modifying connectivity in the distributed circuits of mental illness. His laboratory studies rodent models for prototyping these new technologies and human patients to identify biomarkers and targets for future intervention. He also co-leads programs to design new neurostimulation technologies in the central and peripheral nervous systems, to evaluate technologies for safety and efficacy in humans, and to improve the quality of clinical biomarker research nationwide.
Acknowledgement of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Questions? Email Certificate@AmedcoEmail.com
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed in the agenda. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.
Medtronic:Research Grant Overall Principal Investigator